AzTrials
AzTrials

Osteoarthritis in the KneeNCT03679507

The Effect of Low Intensity Ultrasound Therapy on Chronic Pain Due to Osteoarthritis of the Knee.

A study testing Low Intensity Ultrasound Therapy and Enhancing CBD oil penetration into joints by sonophresis in people with Osteoarthritis in the Knee, run by Dr. Kevin Rod at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To evaluate a new, low intensity ultrasound device in the treatment of chronic pain due to osteoarthritis in the knee. Enhancing CBD oil penetration into joints by sonophoresis. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Osteoarthritis in the Knee
What is being tested?
Low Intensity Ultrasound Therapy and Enhancing CBD oil penetration into joints by sonophresis
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
84 participants
Where
1 siteCanada
Study dates
15 Jun 2019to Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Osteo-arthritis of knee joint diagnosed through X-Ray evaluation
  • Moderate or sever level of pain due to knee osteoarthritis and no other known reason
  • Male of Female patients of 18 to 85 years old
  • Pain interfering with activities of daily life

Who cannot join

  • Cancer pain or any other concurrent cancerous condition
  • History of Knee replacement surgery in the study joint
  • Local infection or any kind of inflammatory or allergic skin lesion
  • Rheumatoid arthritis
  • Mobility disorders or not being able to walk

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Toronto Poly Clinic

    Toronto, Ontario, M2N 6K7

Other trials in Canada

About this study

To evaluate a new, low intensity ultrasound device in the treatment of chronic pain due to osteoarthritis in the knee.

Enhancing CBD oil penetration into joints by sonophoresis.

Read the detailed description

Materials and Methods:

Inclusion criteria:

  1. Osteo-arthritis of knee joint diagnosed through X-Ray evaluation
  2. Moderate or sever level of pain due to knee osteoarthritis and no other known reason
  3. Male of Female patients of 18 to 85 years old
  4. Pain interfering with activities of daily life

Exclusion criteria:

  1. Cancer pain or any other concurrent cancerous condition
  2. History of Knee replacement surgery in the study joint
  3. Local infection or any kind of inflammatory or allergic skin lesion
  4. Rheumatoid arthritis
  5. Mobility disorders or not being able to walk

Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group. Assuming 60% of subjects in Group A show some improvement, as do 30% of patients in Group B, total enrolment of 84 patients (42 per group) will yield statistically significant results (p=0.05; 80% power).

A Study Administrator will assign subjects to a treatment group randomly, and keep this information strictly confidential. Subjects and investigators will be blinded. The Study Administrator will assign each participant a randomly generated Patient ID number to be used in the collection of data.

Subjects will provide in advance written consent to participate in the study, in accordance with Health Canada requirements. Participating subjects will provide baseline pain assessments prior to their first treatment using a 10-point Numeric Pain Scale. They will indicate their current level of pain, and the best and worst pain experienced in the previous 24 hours. An average of these three ratings will be noted. Additionally, participants will complete a Brief Pain Inventory, indicating the location(s) of their pain as well as its impact on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life.

Group A: The first patient group will receive ultrasound therapy on the affected knee joint, using the CPI-LIPUS Device (Circuit Plus Inc., Richmond Hill, Ontario). This low intensity pulsed ultrasonic system operates at 1 MHz for a fixed time of 5 minutes, with a pulsed repetition of 1 kHz. Its total acoustic power is 6.3 W 5%, equivalent to 1.2 W/cm2 acoustic intensity. (Complete technical specifications of and instructions for CPI-LIPUS are attached as Appendix I.) Ultrasound treatment will be pulsed at 50%.

The head of device will be applied to the most painful area of the knee (typically the medial or lateral upper quadrant) for one cycle of five minutes using ultrasound conductive media providing rotating movements, applying only enough pressure to provide adequate coupling of treatment head and the treatment area.

Group B: Group B will be "treated" with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light. The head of the device will be applied to the most painful area of the knee (typically the medial or lateral upper quadrant) for five minutes exactly in the same manner as the Group A.

Treatment of all patients will take place at Toronto Poly Clinic, Toronto Ontario, a multi-disciplinary clinic focused on the treatment of chronic pain. Lead investigator Dr. Rod is their treating physician. Treatments will be repeated at an interval of seven days. A total of six treatments will be performed. Pain assessments will be conducted prior to each treatment, and at 14 days following the last treatment.

Toronto Poly Clinic follows the College of Physicians and Surgeons of Ontario practice regulations including confidentiality and privacy rules and regulations. Study materials will only have subject/patient ID number.

Participating patients will have free access to their usual analgesic treatments throughout the study. A condition of participation in the trial is the patients' agreement to maintain their current analgesic regimen, without change in medication or dosage.

Once a day, participating subjects will rate their joint pain and ease of use of the joint on 10-point Likert scales. They will also record any use of analgesic medication. These data will be noted in Patient Diaries, whose only identifier will be the Patient ID number for maintaining full confidentiality and privacy.

Data from pain assessments, and from the Patient Diaries, will be analyzed to determine the impact of ultrasound therapy on chronic pain due to osteoarthritis of the knee joint. Statistical significance will be assessed.

Data safety: All study materials, diaries, assessments and clinical notes collectively called data will be kept in secure server of the clinic for electronic data or locked cabinet of a secure area in clinic for paper data documents.

Being tested
Low Intensity Ultrasound Therapy, Enhancing CBD oil penetration into joints by sonophresis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low Intensity Ultrasound TherapyProcedure or surgery

    Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.

  • Enhancing CBD oil penetration into joints by sonophresisOther

    High CBD oil will be applied to the affected knee of one-half of the recruited subjects.

Study groups in NCT03679507
Study groupRoleWhat they receive
Group AActive comparatorThe first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
Receives: Procedure: Low Intensity Ultrasound Therapy
Group BPlacebo comparatorWill be "treated" with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light.
Receives: Procedure: Low Intensity Ultrasound Therapy
Group B1Active comparatorThe first patient group will receive high CBD oil applied topically to the affected knee joint.
Receives: Other: Enhancing CBD oil penetration into joints by sonophresis
Group B2No interventionThis group of patients will not receive high CBD oil to the affected joint.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity Measure

    Participants who receive treatment using the CPI-LIPUS , a low intensity pulsed ultrasonic device will document any changes to their pain severity on a Brief Pain Inventory numeric scale from 1 to 10, with 1 being no pain, and 10 being the worst pain at each appointment.

    Measured: The outcome will be measured over a period of 6 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Sep 2018
  2. Study start15 Jun 2019
  3. Primary completionDec 2019 (estimated)
  4. Study completionDec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This clinical trial will investigate the safety and efficacy of a new hand-held, low-intensity therapeutic ultrasound (LIPUS) device to treat chronic knee pain in osteoarthritis patients. Osteoarthritis of the knee is painful condition, and a leading cause of disability \[11\]. Two meta-analyses of this application indicate its efficacy in controlling pain \[7,10\]; one in improving function \[10\]. Three randomized, double blind, placebo-controlled studies have been published recently. Two demonstrate the ameliorative effects of low-intensity ultrasound therapy on pain, function and quality of life in patients with knee osteoarthritis \[12,13\]; one showed no significant difference from placebo \[9\]. Significantly, no adverse event was reported in any of these clinical trials. However subjects will have 24 hours phone access and email access to study administrator and study investigator for reporting any type of adverse event and seeking guidance if needed.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
84 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03679507
Sponsor's protocol ID
TPC-5460-204-0918
Status last verified
Sep 2019
First submitted
13 Sep 2018
Last updated
12 Sep 2019
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Low Intensity Ultrasound Therapy and Enhancing CBD oil penetration into joints by sonophresis in people with Osteoarthritis in the Knee, run by Dr. Kevin Rod at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity Measure (time frame: The outcome will be measured over a period of 6 weeks.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in